Kutzkey Tim
CIK 0001614186 Name as filed on the most recent filing
Filed as Kutzkey Tim (89)
246 transaction lines · from 89 filings · filed 2017-10-30 to 2026-02-26 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER Tenaya Therapeutics, Inc. 3 filings
- ISSUER Eikon Therapeutics, Inc. 1 filings
- ISSUER Surrozen, Inc./DE 7 filings
- ISSUER NGM Biopharmaceuticals Inc 62 filings
- ISSUER Rapt Therapeutics, Inc. 11 filings
- ISSUER Constellation Pharmaceuticals Inc 3 filings
- ISSUER Revolution Medicines, Inc. 1 filings
- ISSUER Immune Design Corp. 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
22 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-02-25 |
Tenaya Therapeutics, Inc. TNYA |
S, Open-market sale | 1,862,545 disposed | 0.56 | 1,047,495.31 | Form 4, filing 0001193125-26-076814 | |
| 2026-02-25 |
Tenaya Therapeutics, Inc. TNYA |
S, Open-market sale | 1,649,281 disposed | 0.56 | 927,555.63 | Form 4, filing 0001193125-26-076814 | |
| 2026-02-24 |
Tenaya Therapeutics, Inc. TNYA |
S, Open-market sale | 349,212 disposed | 0.62 | 214,870.14 | Form 4, filing 0001193125-26-076814 | |
| 2026-02-24 |
Tenaya Therapeutics, Inc. TNYA |
S, Open-market sale | 309,228 disposed | 0.62 | 190,267.99 | Form 4, filing 0001193125-26-076814 | |
| 2026-02-23 |
Tenaya Therapeutics, Inc. TNYA |
S, Open-market sale | 162,291 disposed | 0.60 | 96,920.19 | Form 4, filing 0001193125-26-067007 | |
| 2026-02-23 |
Tenaya Therapeutics, Inc. TNYA |
S, Open-market sale | 143,709 disposed | 0.60 | 85,823.01 | Form 4, filing 0001193125-26-067007 | |
| 2026-02-20 |
Tenaya Therapeutics, Inc. TNYA |
S, Open-market sale | 277,769 disposed | 0.61 | 170,800.16 | Form 4, filing 0001193125-26-067007 | |
| 2026-02-20 |
Tenaya Therapeutics, Inc. TNYA |
S, Open-market sale | 245,965 disposed | 0.61 | 151,243.88 | Form 4, filing 0001193125-26-067007 | |
| 2026-02-11 |
Tenaya Therapeutics, Inc. TNYA |
S, Open-market sale | 2,151,458 disposed | 0.68 | 1,464,712.61 | Form 4, filing 0001193125-26-049028 | |
| 2026-02-11 |
Tenaya Therapeutics, Inc. TNYA |
S, Open-market sale | 1,905,115 disposed | 0.68 | 1,297,002.29 | Form 4, filing 0001193125-26-049028 | |
| 2026-02-10 |
Tenaya Therapeutics, Inc. TNYA |
S, Open-market sale | 182,295 disposed | 0.82 | 148,770.95 | Form 4, filing 0001193125-26-049028 | |
| 2026-02-10 |
Tenaya Therapeutics, Inc. TNYA |
S, Open-market sale | 161,422 disposed | 0.82 | 131,736.49 | Form 4, filing 0001193125-26-049028 | |
| 2026-02-06 |
Eikon Therapeutics, Inc. EIKN |
P, Open-market purchase | 1,437,323 acquired | 18.00 | 25,871,814.00 | Form 4, filing 0001193125-26-043320 | |
| 2026-02-06 |
Eikon Therapeutics, Inc. EIKN |
P, Open-market purchase | 630,881 acquired | 18.00 | 11,355,858.00 | Form 4, filing 0001193125-26-043320 | |
| 2026-02-06 |
Eikon Therapeutics, Inc. EIKN |
P, Open-market purchase | 49,556 acquired | 18.00 | 892,008.00 | Form 4, filing 0001193125-26-043320 | |
| 2026-01-20 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 9,568 acquired | 19.60 | 187,531.84 | Form 4, filing 0001193125-26-016980 | |
| 2026-01-20 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 8,484 acquired | 19.60 | 166,285.55 | Form 4, filing 0001193125-26-016980 | |
| 2026-01-16 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 1,358 acquired | 20.00 | 27,160.00 | Form 4, filing 0001193125-26-016980 | |
| 2026-01-16 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 1,204 acquired | 20.00 | 24,080.00 | Form 4, filing 0001193125-26-016980 | |
| 2026-01-15 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 6,303 acquired | 19.89 | 125,360.37 | Form 4, filing 0001193125-26-016980 | |
| 2026-01-15 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 5,590 acquired | 19.89 | 111,179.51 | Form 4, filing 0001193125-26-016980 | |
| 2026-01-14 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 2,927 acquired | 19.99 | 58,505.75 | Form 4, filing 0001193125-26-014101 | |
| 2026-01-14 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 2,596 acquired | 19.99 | 51,889.63 | Form 4, filing 0001193125-26-014101 | |
| 2026-01-13 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 6,609 acquired | 19.80 | 130,885.30 | Form 4, filing 0001193125-26-014101 | |
| 2026-01-13 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 5,861 acquired | 19.80 | 116,071.83 | Form 4, filing 0001193125-26-014101 | |
| 2026-01-06 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 8,003 acquired | 19.89 | 159,157.26 | Form 4, filing 0001193125-26-007847 | |
| 2026-01-06 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 7,097 acquired | 19.89 | 141,139.46 | Form 4, filing 0001193125-26-007847 | |
| 2025-12-05 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 16,381 acquired | 19.54 | 320,099.48 | Form 4, filing 0001193125-25-311404 | |
| 2025-12-05 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 14,503 acquired | 19.54 | 283,401.67 | Form 4, filing 0001193125-25-311404 | |
| 2025-12-04 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 2,791 acquired | 17.35 | 48,415.48 | Form 4, filing 0001193125-25-311404 | |
| 2025-12-04 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 2,475 acquired | 17.35 | 42,933.82 | Form 4, filing 0001193125-25-311404 | |
| 2025-11-13 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 167,307 acquired | 12.65 | 2,116,433.55 | Form 4, filing 0001193125-25-305738 | |
| 2025-11-13 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 148,150 acquired | 12.65 | 1,874,097.50 | Form 4, filing 0001193125-25-305738 | |
| 2024-04-04 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 102,651 acquired | 15.50 | 1,591,090.50 | Form 4, filing 0000950170-24-045110 | |
| 2024-04-04 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 90,897 acquired | 15.50 | 1,408,903.50 | Form 4, filing 0000950170-24-045110 | |
| 2024-04-04 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 102,651 acquired | 15.50 | 1,591,090.50 | Form 4, filing 0000950170-24-042636 | |
| 2024-04-04 |
Surrozen, Inc./DE SRZN |
P, Open-market purchase | 90,897 acquired | 15.50 | 1,408,903.50 | Form 4, filing 0000950170-24-042636 | |
| 2023-11-16 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 5,840 acquired | 0.62 | 3,627.22 | Form 4, filing 0000950170-23-064847 | |
| 2023-11-15 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 16,791 acquired | 0.71 | 11,879.63 | Form 4, filing 0000950170-23-064847 | |
| 2023-01-31 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 176,730 acquired | 5.00 | 883,402.58 | Form 4, filing 0000899243-23-003130 | |
| 2023-01-30 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 7,542 acquired | 5.00 | 37,706.98 | Form 4, filing 0000899243-23-003130 | |
| 2023-01-23 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 9,900 acquired | 5.00 | 49,494.06 | Form 4, filing 0000899243-23-002630 | |
| 2023-01-20 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 500 acquired | 5.00 | 2,498.00 | Form 4, filing 0000899243-23-002375 | |
| 2023-01-19 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 37,639 acquired | 5.00 | 188,104.67 | Form 4, filing 0000899243-23-002375 | |
| 2023-01-12 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 5,378 acquired | 4.95 | 26,602.81 | Form 4, filing 0000899243-23-001854 | |
| 2023-01-11 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 209,000 acquired | 4.76 | 994,840.00 | Form 4, filing 0000899243-23-001694 | |
| 2023-01-10 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 100,070 acquired | 4.84 | 484,518.93 | Form 4, filing 0000899243-23-001694 | |
| 2022-12-12 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 300 acquired | 4.98 | 1,493.01 | Form 4, filing 0000899243-22-038465 | |
| 2022-11-22 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 4,330 acquired | 5.00 | 21,646.10 | Form 4, filing 0000899243-22-036912 | |
| 2022-11-21 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 35,997 acquired | 5.00 | 179,941.80 | Form 4, filing 0000899243-22-036912 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 22
- Open-market sale 0
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. Kutzkey Tim, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001614186
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6